IE37292L - Mineral salt preparation - Google Patents
Mineral salt preparationInfo
- Publication number
- IE37292L IE37292L IE730252A IE25273A IE37292L IE 37292 L IE37292 L IE 37292L IE 730252 A IE730252 A IE 730252A IE 25273 A IE25273 A IE 25273A IE 37292 L IE37292 L IE 37292L
- Authority
- IE
- Ireland
- Prior art keywords
- weight
- sodium
- parts
- magnesium
- salts
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 6
- 229910052500 inorganic mineral Inorganic materials 0.000 title abstract 4
- 239000011707 mineral Substances 0.000 title abstract 4
- 235000002639 sodium chloride Nutrition 0.000 abstract 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 4
- 239000011734 sodium Substances 0.000 abstract 4
- 229910052708 sodium Inorganic materials 0.000 abstract 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 3
- 239000011575 calcium Substances 0.000 abstract 3
- 229910052791 calcium Inorganic materials 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 235000010755 mineral Nutrition 0.000 abstract 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 2
- 239000011777 magnesium Substances 0.000 abstract 2
- 229910052749 magnesium Inorganic materials 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 101000653791 Bos taurus Protein S100-A12 Proteins 0.000 abstract 1
- 150000000994 L-ascorbates Chemical class 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 150000002315 glycerophosphates Chemical class 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
- 229920002994 synthetic fiber Polymers 0.000 abstract 1
- 150000003892 tartrate salts Chemical class 0.000 abstract 1
- 230000005068 transpiration Effects 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1356097 Mineral salt preparations F HOFFMANNLA ROCHE & CO AG 23 Feb 1973 [25 Feb 1972] 9054/73 Heading A5B Mineral salt preparations having delayed electrolyte release for the continuous replacement of mineral salts lost by bodily stress and increased transpiration as well as by the use of diuretics, comprises a matrix suitable for imparting slow-release characteristics and in the form of salts 5 to 80 parts by weight of calcium, 5 to 40 parts by weight of magnesium. 2 to 20 parts by weight of potassium and no sodium of less than 20 parts by weight of sodium; the calcium, magnesium and sodium constituting more than 10% by weight of the preparation. The salts may be the appropriate halides, sulphates, phosphates, glycerophosphates, tartrates, citrates or ascorbates. A preferred preparation contains calcium and magnesium glycerophosphates and sodium and potassium chlorides. The preparations may be administered orally in the form of tablets, drage s or capsules and may also contain vitamins C, B 1 and B 6 and/or citric acid. The tablets may have a matrix of natural or synthetic material such as wax, e.g. hardened castor oil.
[GB1356097A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH272072 | 1972-02-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE37292L true IE37292L (en) | 1973-08-25 |
| IE37292B1 IE37292B1 (en) | 1977-06-22 |
Family
ID=4240086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE252/73A IE37292B1 (en) | 1972-02-25 | 1973-02-19 | Mineral salt preparation |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS4896717A (en) |
| AT (1) | AT322744B (en) |
| AU (1) | AU451930B2 (en) |
| BE (1) | BE795828A (en) |
| CA (1) | CA1023990A (en) |
| DE (1) | DE2305980A1 (en) |
| FR (1) | FR2173263B1 (en) |
| GB (1) | GB1356097A (en) |
| IE (1) | IE37292B1 (en) |
| IL (1) | IL41412A (en) |
| IT (1) | IT978459B (en) |
| NL (1) | NL7301863A (en) |
| PH (1) | PH10214A (en) |
| ZA (1) | ZA73467B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI834309L (en) * | 1983-11-24 | 1985-05-25 | Pharmaconsult Oy | SALT MIXTURE. |
| US4954349A (en) * | 1987-09-11 | 1990-09-04 | Ciba-Geigy Corporation | Oral magnesium and potassium compositions and use |
| CH677612A5 (en) * | 1987-09-11 | 1991-06-14 | Ciba Geigy Ag | |
| US5035898A (en) * | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
| FI120290B (en) * | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | Process by which such herbal, food component and food compositions can be made which reduce serum cholesterol |
| FR2773955B1 (en) * | 1998-01-26 | 2000-04-07 | Sanofi Sa | DIETETIC COMPOSITION IN THE FORM OF A SALT SUBSTITUTING TABLE SALT |
| FR2931359B1 (en) | 2008-05-20 | 2012-12-21 | Menvielle Bourg Fabienne Joanny | USE OF MATRIX FOR EXTENDED RELEASE MAGNESIUM ORAL DELIVERY, AND COMPOSITION CONTAINING SAME |
| FR2931361B1 (en) | 2008-05-20 | 2012-08-31 | Menvielle Bourg Fabienne Joanny | MAGNESIUM-BASED SYSTEM AND ITS USE IN COSMETICS |
| EP2813217A1 (en) | 2013-06-11 | 2014-12-17 | Fabienne Joanny Menvielle-Bourg | Composition for oral administration of magnesium, in association with a composition for the treatment of type 2 diabetes and its complications |
| FR3024019B1 (en) * | 2014-07-28 | 2017-11-24 | Yvan Erbs | FOOD SUPPLEMENT FOR IMPROVING THE FUNCTIONING OF LIVING CELLS AND ASSOCIATED METHOD |
| US20210196748A1 (en) * | 2019-12-30 | 2021-07-01 | Robert Olson | Composition and therapy for treatment of gag reflexes |
-
1973
- 1973-01-22 ZA ZA730467A patent/ZA73467B/en unknown
- 1973-01-25 IT IT19595/73A patent/IT978459B/en active
- 1973-01-25 AU AU51455/73A patent/AU451930B2/en not_active Expired
- 1973-01-29 IL IL41412A patent/IL41412A/en unknown
- 1973-02-07 DE DE2305980A patent/DE2305980A1/en not_active Withdrawn
- 1973-02-09 NL NL7301863A patent/NL7301863A/xx unknown
- 1973-02-16 PH PH14350*A patent/PH10214A/en unknown
- 1973-02-19 IE IE252/73A patent/IE37292B1/en unknown
- 1973-02-23 BE BE795828D patent/BE795828A/en unknown
- 1973-02-23 CA CA164,470A patent/CA1023990A/en not_active Expired
- 1973-02-23 FR FR7306517A patent/FR2173263B1/fr not_active Expired
- 1973-02-23 GB GB905473A patent/GB1356097A/en not_active Expired
- 1973-02-23 JP JP48021406A patent/JPS4896717A/ja active Pending
- 1973-02-23 AT AT163273A patent/AT322744B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU451930B2 (en) | 1974-08-22 |
| GB1356097A (en) | 1974-06-12 |
| PH10214A (en) | 1976-09-29 |
| JPS4896717A (en) | 1973-12-10 |
| DE2305980A1 (en) | 1973-08-30 |
| IL41412A (en) | 1976-04-30 |
| FR2173263A1 (en) | 1973-10-05 |
| BE795828A (en) | 1973-08-23 |
| AU5145573A (en) | 1974-07-25 |
| ZA73467B (en) | 1973-10-31 |
| AT322744B (en) | 1975-06-10 |
| IT978459B (en) | 1974-09-20 |
| IE37292B1 (en) | 1977-06-22 |
| IL41412A0 (en) | 1973-03-30 |
| CA1023990A (en) | 1978-01-10 |
| NL7301863A (en) | 1973-08-28 |
| FR2173263B1 (en) | 1975-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000045770A3 (en) | Compressed lecithin preparations | |
| IE37292B1 (en) | Mineral salt preparation | |
| IL76138A (en) | Pharmaceutical formulation in the form of sucralfate suspension and its preparation | |
| IE45655L (en) | Gastric reflux treatment composition | |
| IL58697A0 (en) | Analgesic pharmaceutical compositions in the form of effervescent powders comprising metoclopramide | |
| ATE75941T1 (en) | POWDERY HYDROPHILIC THEOPHYLLINE FORMULATION AND PROCESS FOR PRODUCTION. | |
| EP0237241A3 (en) | Calcium supplement compressed tablets | |
| DE2963990D1 (en) | Analgesic tablet and process for its preparation | |
| JP2001527022A5 (en) | ||
| GB1464200A (en) | Pharmaceutical composition | |
| ES8705763A1 (en) | Pharmaceutical compositions containing gels. | |
| GB1191246A (en) | Vitamin-containing Preparations | |
| JPS57152858A (en) | Acesulfam containing composition and production thereof | |
| GB1403900A (en) | Pharmaceutical composition | |
| GB1355985A (en) | Solid slow release preparation of prolonged action | |
| GB1344558A (en) | Method for treating diseases by coenzyme a and adenosine triphosphate and composition therefor | |
| IE34077B1 (en) | Dentifrice compositions | |
| EP0377119A1 (en) | Agent for reducing adverse effects of table salt | |
| FR2567402B1 (en) | NOVEL PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING DIHYDROXY-1,8 PHENYL-10 ANTHRONE-9 AS ACTIVE INGREDIENT, AND PROCESS FOR PREPARING THE ACTIVE INGREDIENT | |
| Matsumoto et al. | Mechanism of material deformation related to shape and crown phenomena | |
| DE2743702A1 (en) | Slimming or weight-loss preparation and method for its preparation | |
| GB1275816A (en) | Improvements in or relating to dentifrices | |
| IE34386B1 (en) | Pharmaceutical compositions | |
| GB1054698A (en) | ||
| MY107599A (en) | Sucralfate suspension compounds. |